Related references
Note: Only part of the references are listed.B7-H3: An Attractive Target for Antibody-based Immunotherapy
Filippos Kontos et al.
CLINICAL CANCER RESEARCH (2021)
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Ezra Y. Rosen et al.
CLINICAL CANCER RESEARCH (2021)
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)
Saiama N. Waqar et al.
CLINICAL LUNG CANCER (2021)
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2021)
Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression
Philip Vitorino et al.
TRANSLATIONAL ONCOLOGY (2021)
Unlocking the potential of antibody-drug conjugates for cancer therapy
Joshua Z. Drago et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors
Yutaka Fujiwara et al.
CANCER MEDICINE (2021)
HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
Kimio Yonesaka
CANCERS (2021)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
K. Nakagawa et al.
Journal of Thoracic Oncology (2021)
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Robert L. Coleman et al.
LANCET ONCOLOGY (2021)
The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Natalya D. Bodyak et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
Soren Weidemann et al.
BIOMEDICINES (2021)
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Sekwon Jang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Pasi A. Janne et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Considerations for the Design of Antibody-Based Therapeutics
Dennis R. Goulet et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack et al.
CLINICAL CANCER RESEARCH (2020)
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
David M. O'Malley et al.
GYNECOLOGIC ONCOLOGY (2020)
U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
Koji Haratani et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
Egbert F. Smit et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).
Aaron Elliott Lisberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).
Debra L. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Raffit Hassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
Junji Tsurutani et al.
Cancer Discovery (2020)
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Bob T. Li et al.
CANCER DISCOVERY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
Kathleen N. Moore et al.
GYNECOLOGIC ONCOLOGY (2020)
SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study
Daniel Morgensztern et al.
LUNG CANCER (2020)
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Leisha A Emens et al.
LANCET ONCOLOGY (2020)
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer
Juniper A. Scribner et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma
Patrick A. Ott et al.
CANCER (2019)
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Johann S. de Bono et al.
LANCET ONCOLOGY (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
Samaresh Sau et al.
CANCERS (2019)
A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)
Kiichiro Ninomiya et al.
CHEST (2019)
Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met plus non-small cell lung cancer by EGFR mutation status.
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.
Malaka Ameratunga et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine
Vadim Le Joncour et al.
MOLECULAR CANCER THERAPEUTICS (2019)
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization
Yuuri Hashimoto et al.
CLINICAL CANCER RESEARCH (2019)
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Daniel Morgensztern et al.
CLINICAL CANCER RESEARCH (2019)
Antibody-drug conjugates for cancer
Cindy H. Chau et al.
LANCET (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1739OA phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC)
C Hann et al.
ANNALS OF ONCOLOGY (2019)
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P. Robichaux et al.
CANCER CELL (2019)
First-In-Human Phase 1/2 Trial of Anti-AXL Antibody-Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC
S. Ramalingam et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study
Camille Mehlman et al.
LUNG CANCER (2019)
Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Kerry A. Whalen et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells
Maxine Bauzon et al.
ONCOIMMUNOLOGY (2019)
A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer
Lucia D'Amico et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer
Louise A. Koopman et al.
JCI INSIGHT (2019)
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters et al.
CLINICAL CANCER RESEARCH (2019)
Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
Matthew Sung et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Antibody-Drug Conjugates for Cancer Treatment
John M. Lambert et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer
Katsuyuki Hotta et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Guangmin Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
Julia Boshuizen et al.
NATURE MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
Erika Paige Hamilton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2018)
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
John H. Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
Nirnoy Dan et al.
PHARMACEUTICALS (2018)
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence
Jieyi Wang et al.
CLINICAL CANCER RESEARCH (2017)
Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix
Remy Gebleux et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
Rebecca Suk Heist et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
H. L. Kindler et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin et al.
LANCET ONCOLOGY (2017)
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Julian Andreev et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer
April A. N. Rose et al.
PHARMACOLOGY & THERAPEUTICS (2017)
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
Marc Damelin et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients
Zhaoxuan Zhang et al.
TUMOR BIOLOGY (2017)
The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates
Mark Frigerio et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2017)
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2017)
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity
Carla Rios-Luci et al.
CANCER RESEARCH (2017)
Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells
Hongbin Wang et al.
CANCER SCIENCE (2017)
Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies
Jonathan Rios-Doria et al.
CANCER RESEARCH (2017)
Giving AXL the axe: targeting AXL in human malignancy
Carl M. Gay et al.
BRITISH JOURNAL OF CANCER (2017)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
Joanna H. Tong et al.
CLINICAL CANCER RESEARCH (2016)
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
Sinead A. Noonan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Scientific Advances in Lung Cancer 2015
Anne S. Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63
Bart E. C. G. de Goeij et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The effects and mechanisms of SLC34A2 on tumorigenicity in human non-small cell lung cancer stem cells
Zhanxin Jiang et al.
TUMOR BIOLOGY (2016)
Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells
Moses O. Oyewumi et al.
ONCOTARGET (2016)
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
Jessica R. McCombs et al.
AAPS JOURNAL (2015)
Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells
Kyung-Chan Kim et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer
Denise A. Yardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents
Giulio Casi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Frank Loganzo et al.
MOLECULAR CANCER THERAPEUTICS (2015)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton et al.
CANCER DISCOVERY (2015)
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
Anish Thomas et al.
ONCOTARGET (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer
Yixiang Mao et al.
ONCOTARGET (2015)
MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung
Hans-Ulrich Schildhaus et al.
CLINICAL CANCER RESEARCH (2015)
The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer
Yu Wang et al.
JOURNAL OF BIOMEDICAL SCIENCE (2015)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)
Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates
Russ Wada et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
Esther C. W. Breij et al.
CANCER RESEARCH (2014)
Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
Stefan S. Kachala et al.
CLINICAL CANCER RESEARCH (2014)
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
Johanna Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Sven Golfier et al.
MOLECULAR CANCER THERAPEUTICS (2014)
A general approach to site-specific antibody drug conjugates
Feng Tian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Higher Expression of Receptor Tyrosine Kinase Axl, and Differential Expression of its Ligand, Gas6, Predict Poor Survival in Lung Adenocarcinoma Patients
Masashi Ishikawa et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway
Xi Wang et al.
CANCER BIOLOGY & THERAPY (2013)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma
Aigui Jiang et al.
ONCOLOGY LETTERS (2013)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer A Meta-Analysis of Published Data
Lingxiang Liu et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Fumin Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Increased Tissue Factor Expression Is Associated with Reduced Survival in Non-Small Cell Lung Cancer and with Mutations of TP53 and PTEN
Sandra Regina et al.
CLINICAL CHEMISTRY (2009)
Role of Tissue Factor in Cancer
Raj S. Kasthuri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients
Zuleyha Calikusu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Greg M. Thurber et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion
Yih-Wen Chen et al.
CURRENT CANCER DRUG TARGETS (2008)
Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer
Shoichi Kuyama et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Tissue factor expression in non-small cell lung cancer:: Relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation
Sandra Regina et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Targeting the function of the HER2 oncogene in human cancer therapeutics
M. M. Moasser
ONCOGENE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
Jennifer A. A. Gubbels et al.
MOLECULAR CANCER (2006)
Twist mediates suppression of inflammation by type IIFNs and Axl
M. Nusrat Sharif et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
B7-H3 and B7-H4 expression in non-small-cell lung cancer
Yuping Sun et al.
LUNG CANCER (2006)
Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysis
H Nakamura et al.
CANCER (2005)
Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides
A Suenaga et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
A Rump et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Intragenic ERBB2 kinase mutations in tumours
P Stephens et al.
NATURE (2004)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types - An immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura
M Miettinen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
FR Hirsch et al.
BRITISH JOURNAL OF CANCER (2002)
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-Doxorubicin in patients with Lewis Y-expressing epithelial tumors
MN Saleh et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
